Korean J Helicobacter  Up Gastrointest Res Search


Korean J Helicobacter  Up Gastrointest Res > Volume 17(4); 2017 > Article
The Korean Journal of Helicobacter  and Upper Gastrointestinal Research 2017;17(4):179-184.
DOI: https://doi.org/10.7704/kjhugr.2017.17.4.179    Published online December 10, 2017.
Chemoprevention of Gastric Cancer: Metformin
Young Il Kim, Soo Jeong Cho
Center for Gastric Cancer, National Cancer Center, Goyang, Korea. crystal522@ncc.re.kr
위암의 화학 예방 요법: 메트포르민
김영일, 조수정
국립암센터 위암센터
Received: 10 October 2017   • Revised: 8 November 2017   • Accepted: 9 November 2017
Metformin is a first-line anti-diabetic drug that has been widely used in patients with type 2 diabetes. Many population-based epidemiologic studies have shown that metformin treatment is associated with decreased risk for various cancers. Recent epidemiologic studies showed that the use of metformin was associated with a reduction in gastric cancer risk, especially in patients with type 2 diabetes who used metformin for long periods of time (>2~3 years). Currently, there are no registered clinical trials investigating the anti-cancer effect of metformin in gastric cancer; hence, further well-designed clinical trials are required. Herein, we review the literature regarding the use of metformin for the prevention of gastric cancer.
Key Words: Chemoprevention; Metformin; Stomach neoplasms

Editorial Office
Lotte Gold Rose II Room 917, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-565-9946    Fax: +82-2-565-9947    E-mail: hpylori@kams.or.kr                

Copyright © 2023 by Korean College of Helicobacter and Upper Gastrointestinal Research.

Developed in M2PI

Close layer
prev next